Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barry Jarnagin

Urogynecology and Reconstructive Pelvic Surgery Franklin, TN Medical Doctor

NPI 1194806323 CMS profile 189955

100 Covey Dr, Suite 205, Franklin, TN 37067

Open in the dashboard

General payments

$57,422

447 records reported · program years 2019–2025

Research payments

$11,055

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$164,399 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Barry Jarnagin of Franklin, TN is reported in the CMS Open Payments database as having received $57,422 across 447 general payments and $11,055 in research payments paid to them. Separately, studies naming them as principal investigator received $164,399 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,001 12
2024 General $722 44
2023 General $9,154 68
2022 General $1,849 67
2021 General $12,674 82
2021 Research $11,055 2
2020 General $10,822 75
2019 General $14,202 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barry Jarnagin
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Barry Jarnagin were reported at $8,001. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Barry Jarnagin Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $14,202 $358 $132–$1,270 $163
2020 $10,822 $198 $86–$642 $114
2021 $12,674 $361 $118–$1,182 $132
2022 $1,849 $410 $128–$1,175 $149
2023 $9,154 $434 $152–$1,344 $160
2024 $722 $494 $193–$1,331 $164
2025 $8,001 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Caldera Medical, Inc $12,653 22 payments
  2. Boston Scientific Corporation $12,271 54 payments
  3. Inspire Medical Systems, Inc. $7,440 6 payments
  4. Astellas Pharma US Inc $6,005 44 payments
  5. AbbVie, Inc. $3,350 38 payments
  6. Duchesnay USA Incorporated $3,346 10 payments
  7. Celularity, Inc. $3,235 11 payments
  8. CooperSurgical, Inc. $3,071 5 payments
  9. Axonics Modulation Technologies, Inc. $2,518 53 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $628 35 payments
  11. Other $2,906 169 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,065 8 payments
  2. Consulting Fee $16,103 8 payments
  3. Food and Beverage $10,118 367 payments
  4. Honoraria $6,451 2 payments
  5. Travel and Lodging $3,087 20 payments
  6. Education $325 38 payments
  7. Gift $273 4 payments
Products named General payments · program years 2019–2025
  1. Desara $12,653 22 payments
  2. INSPIRE $7,440 6 payments
  3. Veozah $5,380 7 payments
  4. SOLYX $5,125 15 payments
  5. Osphena $3,346 10 payments
  6. ORILISSA $2,935 19 payments
  7. CAPIO $2,775 1 payment
  8. Uterine Manipulators & Injectors $2,694 3 payments
  9. OBTRYX $2,255 1 payment
  10. Axonics r-SNM System $1,460 22 payments
  11. Other $11,896 375 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Integra LifeSciences Corporation $11,055 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

368

Median for Obstetrics & Gynecology: 65

Drug cost

$59,501

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

42.9%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 37 $22,752
Myrbetriq Mirabegron Brand 36 $17,952
Linzess Linaclotide Brand 18 $9,075
Estradiol Generic 56 $3,345
Osphena Ospemifene Brand 12 $2,877
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 21 $903
Solifenacin Succinate Generic 39 $837
Methenamine Hippurate Generic 26 $750
Amitriptyline Hcl Generic 26 $488
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 11 $154

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$46,595

Medicare's payments for the services billed

Medicare patients

100

Average age 73

Services billed

1,227

100 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 50%
Depression 27%
Cancer 20%
Diabetes 17%
Osteoporosis 15%
Ischemic heart disease 14%
COPD 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $123
$123 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $107
  • PFIZER INC. $14
$121 — —
BOTOX
  • AbbVie, Inc. $113
$113 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $65
$65 37 —
PREMARIN
  • PFIZER INC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

449 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record